Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Efficacy of c-erbB-2 antisense oligonucleotide transf ection on uterine endometrial cancer HEC-1 A cell lines
1Obstetrics and Gynecology Department, China
2Infectious Disease Laboratory, China
3Central Laboratory, 4Biochemical Department, Shengjing Hospital, China Medical University, Shenyang, China
*Corresponding Author(s): F.J. Zhao E-mail:
Objective: Antigene therapy targeting only one oncogene has made much progress although it still has some limitations. To explore the potential for antigene therapy in uterine endometrial cancer, we examined the in vitro inhibitory effects of liposmal anti-sense phosphorothioate oligonucleotides targeting c-erbB-2 in the human uterine endometrial cancer HEC-1A cell line.
Methods: 1) To detect c-erbB-2 protein expression on HEC-1A cell membranes by immunohisto- chemistry. 2) To assay cellular growth inhibition by MTT after transfecting 0.1-0.6 microM ASODN. 3) To observe cellular and ultra-structural changes under transmission electron microscope and to assay the cellular apoptotic rate by flow cytometry and c-erbB-2 mRNA, and protein expression by RT-PCR and Western blot after transfecting 0.3 microM ASODN.
Results: 1) c-erbB-2 protein expression was positive on HEC-1A cell membranes. 2) With the increase of the transfecting ASODN concentration from 0.1-0.6 microM, HEC-1A cellular growth inhibition was also enhanced. The results of MTT showed that when the transfecting concentration of ASODN was 0.3 microM, the HEC-1A cellular growth inhibition rate was 50% while when the transfecting concentration of ASODN was 0.6 microM, the HEC-1A cell growth inhibition rate was 75%. 3) When the concentration of transfecting ASODNs was 0.3 microM, there were obvious vacuolar degenerations in the plasma of HEC-1A cells, disappearance of organelle and nuclear structure and obvious shrinkage of nuclei under transmission electron microscope. The cellular apoptotic rate was 62.80%, while c-erbB-2 mRNA and protein expression were 47.18% and 33.60%, respectively, compared with those of the normal control cells.
Conclusion: Transfecting c-erbB-2 ASODNs can obviously suppress the mRNA and protein expression in HEC-1A cells, cause cellular apoptosis and inhibit cell growth. It may be a more useful gene therapy for endometrial cancer.
Antisense; Oligodeoxynucleotides; Transfection; Uterine endometrial neoplasms
F.J. Zhao,S.L. Zhang,L. Ma,H. Gao,Z.H. Zhong. Efficacy of c-erbB-2 antisense oligonucleotide transf ection on uterine endometrial cancer HEC-1 A cell lines. European Journal of Gynaecological Oncology. 2007. 28(4);263-269.
[1] Enomoto T., Inoue M., Perantoni A.O., Buzard G.S., Miki H., Tanizawa O., Rice J.M.: "K-ras activation in premalignant and malignant epithelial lesions of the human uterus". Cancer Res., 1991, 51, 5308.
[2] Cirisano F.D., Karlan B.Y.: "The role of the HER-2/neu oncongen in gynecologic cancers". J. Soc. Gynecol. Investing., 1996, 3, 99.
[3] Rubin 1., Yarden Y.: "The basic biology of HER-2". Ann. Oneal., 2001, 12 (suppl. I), S3.
[4] Eccles S.A.: "Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signaling". Recent Results Cancer Res., 2000, 157, 41.
[5] Rait A.S., Pirollo K.F., Rait V. et al.: "Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer". Cancer Gene Ther., 2001, 8, 728.
[6] Kazuaki T., Ryungsa K., Hideki I. et al.: "Antisense bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs". Int. J. Oncol., 2003, 22, 875.
[7] Trost T.M., Lausch E.U., Fees S.A. et al.: "Premature senescence is a primary fail-safe mechanism of ERBB-2-driven tumorigenesis in breast carcinoma cells". Cancer Res., 2005, 65, 840.
[8] Yang S.P., Song S.T., Song H.F.: "Advancements of ant1sense oligonucleotide in treatment of breast cancer". Acta P harmocol. Sin., 2003, 24, 289.
[9] Rait A.S., Pirollo K.F., Xiang L. et al.: "Tumor targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 level". Mal. Med., 2002, 8,475.
[10] Pack S.D., Alper O.M., Stromberg K. et al.: "Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line". Cancer Res., 2004, 64, 789.
[11] Wu Y.Z., Ren Q.L., Li S.L.: "Therapeutic effects of c-erbB-2 and c-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nudemice". Ai Zheng, 2003, 22, 836.
[12] Fei R., Shaoyang L.: "Combination antigene therapy targetmg cmyc and c-erbB-2 in ·the ovarian cancer COC I) cell line" Gynecol. Oncol., 2002, 85, 40.
[13] Hetzel D.J., Wilson T.O., Keeney G.L. et al.: "HER-2/neu expression: a major prognostic factor in endometrial cancer". Gynecol. Oncol., 1992, 47, 179.
[14] Bigsby R.M., Li A.X., Bomalaski J. et al.: "Immunohistochemical study of HER-2/neu epidermal growth factor re(..eptor and steroid receptor expression in normal and malignant endometrium" Obstet. Gynecol., 1992, 79, 95.
[15] Berchuck A., Rodriguez G., Kinny R.B. et al.: "Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease". Am. J. Obstet. Gynecol., 1991, 164, 15.
[16] Desheng Y., Li L., Bujiang T. et al.: "C-erbB-2 oncoprotem expression in endometrial carcinoma and its relationship to clinical course and prognosis". J. Clin. Oneal. (China), 1997, 2, 12.
[17] Saffari B., Jones L.A., el-Naggar A. et al.: "Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival". Cancer Res., 1995, 55, 5693.
[18] Rolitsky C.D., Theil K.S., Mc Gaughy V.R. et al.: "HER-2/neu amplification and overexpression in endometrial carcinoma". Int. J. Gynecol. Pathol., 1999, 18, 138.
[19] Rasty G., Murray R., Lu L. et al.: "Expression of HER-2/neu oncogene in normal, hyperplastic and malignant endometrium" Ann. Cli. Lab. Sci., 1998, 28, 138.
[20] Kohlberger P., Loesch A., Koelbl H. et al.: "Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer". Cancer Lett., 1996, 98, 151.
[21] Kunamaru T., Takagi T., Takakura Y. et al.: "Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes". J. Drug. Target, 1998, 5, 235.
[22] Magin-Lachmann C., Kotzamanis G., D'Aiuto L. et al.: "In vitro and in vivo delivery of intact BAC DNA-comparison of different methods". J. Gen. Med., 2004, 6, 195.
[23] Magin-Lachmann C., Kotzamanis G., D'Aiuto L. et al.: "Retrofitting BACs with G418 resistance, luciferase and oriP and EBNAI- new vectors for in vitro and in vivo delivery". BMC Biotechnol., 2003, 3, 2.
[24] Ohki E.C., Tilkins M.L., Ciccarone V.C. et al.: "Improving the transfection efficiency of post-mitotic neurons". J. Neurosci Meth., 2001, 112, 95.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top